32.4 million revenue surges over 20 percent with regulatory wins, Stereotaxis asserts

32.4 million revenue surges over 20 percent with regulatory wins, Stereotaxis asserts
Stereotaxis revenue jumps 20 percent

Stereotaxis reported revenue of 32.4 million, marking growth exceeding 20 percent compared to the previous year.

The company announced regulatory approvals for its GenesisX, MAGiC, and MAGiC Sweep technologies. Stereotaxis also established key manufacturing and commercial foundations as it prepares to launch new technology and pursue further business expansion. The company emphasized its commitment to accelerating growth and driving innovation within its sector.

Stereotaxis’s ongoing momentum builds on its longstanding efforts to enhance patient and physician safety, as highlighted by its advancements in robotic technology that shields patients and doctors from radiation during complex procedures. The company’s push for broader adoption is further underscored by past initiatives to offer practitioners a direct experience of RoboticEP benefits through interactive demonstration, reinforcing its position at the forefront of innovation in interventional medicine.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.